2005, Número 2
Metástasis óseas de primario desconocido. Reporte de un caso
Contreras CNA, Sosa SR, Dan Green RD
Idioma: Español
Referencias bibliográficas: 22
Paginas: 122-128
Archivo PDF: 340.30 Kb.
RESUMEN
La gran mayoría de tumores óseos son de origen metastático. Los diferentes tipos histológicos de los tumores pueden invadir el hueso por extensión inmediata del sitio primario, por vía hematógena o linfática. La destrucción ósea es por lo general suficientemente importante para debilitarlo y causar fracturas patológicas, presentes hasta en el 30% de los casos de afección metastásica ósea.
REFERENCIAS (EN ESTE ARTÍCULO)
Longo F, Mansueto G. [ESMO Conference 2004. Ibandronate in the treatment of bone metastasis]. Tumori 2004; 90(6): 30-5.
Longo F, Mansueto G. [AIOM Conference 2004. Endocrine therapy and management of patients with bone metastasis of breast cancer]. Tumori 2004; 90(6): 1-12.
Novikov SN. [Methodology of bone marrow imaging in diagnosis of skeletal metastatic involvement in cancer patients]. Vopr Onkol 2004; 50(6): 711-5.
Gasbarrini A, Cappuccio M, Mirabile L, Bandiera S, Terzi S, Barbanti Brodano G, Boriani S. Spinal metastases: treatment evaluation algorithm. Eur Rev Med Pharmacol Sci 2004; 8(6): 265-74.
Abroszkiewicz J, Gajewska J, Laskowska-Klita T, Wozniak W. [Biochemical bone resorption markers in children with osteosarcoma]. Med Wieku Rozwoj 2004; 8(2 Pt 1): 225-33.
Ogiso S, Maeno A, Nagahama K, Nakamura K, Okuno H. [Small intestinal metastases from renal cell carcinoma: a case report and literature review]. Hinyokika Kiyo 2005; 51(1): 13-6.
Sabino MA, Mantyh PW. Pathophysiology of bone cancer pain. J Support Oncol 2005; 3(1): 15-24.
Abstracts of the Fourth International Conference on Cancer-Induced Bone Diseases. December 7-9, 2003. San Antonio, Texas, USA. J Bone Miner Res 2004; 19(9): 1559-600.
Luo CC. Spinal cord compression secondary to metastatic non-Hodgkins lymphoma: a case report. Arch Phys Med Rehabil 2005; 86(2): 332-4.
Hof H, Debus J. [Treatment of metastases—the place of radiotherapy]. MMW Fortschr Med 2005; 147(1-2): 31-3.
Fuchs B, Trousdale RT, Rock MG. Solitary bony metastasis from renal cell carcinoma: significance of surgical treatment. Clin Orthop Relat Res 2005; (431): 187-92.
Vieillard MH, Boutry N, Chastanet P, Duquesnoy B, Cotten A, Cortet B. Contribution of percutaneous biopsy to the definite diagnosis in patients with suspected bone tumor. Joint Bone Spine 2005; 72(1): 53-60.
Strugnell M, Gibson M, Hopkins R, Lyburn I, McGann G. Case report. Renal cell carcinoma vertebral body metastasis extending into the azygos venous system causing superior vena cava obstruction. Br J Radiol 2005; 78(925): 65-7.
Mercer RR, Miyasaka C, Mastro AM. Metastatic breast cancer cells suppress osteoblast adhesion and differentiation. Clin Exp Metastasis 2004; 21(5): 427-35.
Ishikawa T, Okazaki R. [Pyridinoline, deoxypyridinoline]. Nippon Rinsho 2004; 62 Suppl 12: 224-7.
Hayashi Y. [Bone alkaline phosphatase (BAP)]. Nippon Rinsho 2004; 62 Suppl 12: 210-4.
Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ, McCauley LK. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology 2005; 146(4): 1727-36. Epub 2005 Jan 6.
Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005; 5(1): 21-8.
Katz D, Aharoni D. Images in clinical medicine. Lytic lesions in breast cancer. N Engl J Med 2004; 351(27): 2850.
Chirgwin JM, Mohammad KS, Guise TA. Tumor-bone cellular interactions in skeletal metastases. J Musculoskelet Neuronal Interact 2004; 4(3): 308-18.
Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, Sung J, Raut M, Oster G. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004; 67(5-6): 390-6.
Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97(1): 59-69.